bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.06.12.659313

NDR2 Kinase Regulate Microglial Metabolic Adaptation and Inflammatory Response: Critical Role in Glucose-Dependent Functional Plasticity

Abstract

Diabetes and its retinal complication, diabetic retinopathy (DR), are a rapidly increasing health, societal and economic burden. Diabetic retinopathy is a complex disease with a chronic inflammatory component mediated by retinal microglial cells. Recent studies have demonstrated the importance of the Hippo pathway kinases, Ndr1/Stk38 and Ndr2/Stk38l, in the regulation of macrophages, immune cells that share similarities with microglial cells. However, the role of NDR2 kinases in microglial inflammatory response and in the pathophysiology of diabetic retinopathy has not yet been uncovered. This study investigates the role of NDR2 kinase in microglial cells, particularly in response to high glucose (HG) conditions. Using CRISPR-Cas9, we downregulated Ndr2 kinase in BV-2 microglial cells and analyzed the impact on cellular metabolism, phagocytosis and migratory capabilities. We demonstrate that microglial cells expressed NDR2 kinase protein, especially in HG conditions, suggesting its importance in regulating microglial functions during hyperglycemia. Ndr2 downregulated cells present a decreased basal respiration, indicating an impaired mitochondrial function. They also showed decreased metabolic flexibility to stress conditions, such as adaptation to HG conditions. Functionally, Ndr2 downregulation led to decreased phagocytic capacity and migration of microglial cells, both cytoskeleton-based functions. Furthermore, Ndr2 downregulation resulted in altered cytokine and chemokine secretion profiles. Notably, increased levels of pro-inflammatory cytokines such as IL-6, TNF, IL-17 and IL-12p70 were observed in Ndr2 downregulated cells, even under normal glucose conditions. In conclusion, our findings indicate that NDR2 kinase is crucial for microglial metabolic adaptation to stress, such as high glucose exposure and for influencing microglial inflammatory responses. Therefore, NDR2 kinase plays a vital role in maintaining microglial functional plasticity in response to glucose variations, suggesting potential implications for neuroinflammatory processes in conditions like diabetic retinopathy. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=126 SRC="FIGDIR/small/659313v1_ufig1.gif" ALT="Figure 1"> View larger version (26K): org.highwire.dtl.DTLVardef@1380275org.highwire.dtl.DTLVardef@2950f9org.highwire.dtl.DTLVardef@833593org.highwire.dtl.DTLVardef@325171_HPS_FORMAT_FIGEXP M_FIG C_FIG Research in Context What is already known about this subject?O_LIThe pathogenesis of diabetic retinopathy (DR) involves chronic inflammation mediated by retinal microglial cells, which contribute to vascular damage and neurodegeneration. C_LIO_LIMicroglial dysfunction under high glucose (HG) conditions exacerbates cytokine release and oxidative stress, driving DR progression. C_LIO_LINDR kinases regulate inflammatory pathways in macrophages, but their role in microglia during DR was previously unexplored. C_LI What is the key question?O_LIHow do NDR2 kinase regulate microglial inflammatory responses and functional adaptability in diabetic retinopathy? C_LI What are the new findings?O_LINDR2 expression is upregulated in microglia exposed to HG. C_LIO_LINdr2 downregulation in microglia impairs metabolic flexibility, phagocytosis, and migration. C_LIO_LINdr2 downregulation disrupts cytoskeleton-dependent microglial functions, limiting their ability to adapt to metabolic stress. C_LIO_LINdr2 downregulation in microglia increases pro-inflammatory cytokines (IL-17, TNF) and reduces anti-inflammatory factors (sTNFRI, VEGF), exacerbating inflammation. C_LI How might this impact clinical practice?O_LITargeting Ndr2 signaling could emerge as a therapeutic strategy to modulate microglial-driven inflammation, potentially slowing DR progression and complementing existing glycemic control approaches. C_LI

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Fazendeiro, B., Machado, I., Rolo, A., Rodrigues-Santos, P., Ambrosio, A. F., Santos, P. F., Leger, H. M.. 2025-06-17. NDR2 Kinase Regulate Microglial Metabolic Adaptation and Inflammatory Response: Critical Role in Glucose-Dependent Functional Plasticity. https://doi.org/10.1101/2025.06.12.659313

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

De novo design of CR2 binder as vaccine scaffold

Efficient B cell activation during vaccine-induced humoral immunity relies on both B cell receptor (BCR) antigen recognition and synergistic signaling from co-receptors. Complement receptor 2 (CR2), the primary BCR co-receptor on B cells, lowers the activation threshold and amplifies downstream kinase signaling by orders of magnitude when engaged by complement fragment C3d decorated antigens. Targeting CR2 therefore represents a rational vaccine enhancement strategy, yet native C3d suffers from low affinity, poor stability, and manufacturing challenges. Here, we report the de novo design of a highly stable, high-affinity CR2 binder using deep learning driving protein design methods. Biophysical characterization, high-resolution cryoEM structural determination, and functional assays in vitro and in vivo confirm that the designed binder matches computational design models and specifically engages CR2 to boost B cell activation. When fused to antigen as a vaccine scaffold, the trimeric CR2 binder elicits robust humoral immune responses comparable to nanoparticle vaccines, while retaining the simplicity of single-chain protein production. Our work establishes a modular CR2 targeting vaccine scaffold platform with broad translational potential for next-generation protein vaccines.

immunology↗

Chronic opioid-associated immune dysregulation among people living with HIV

Objectives: Persistent immune dysregulation contributes to chronic disease among people living with HIV (PWH), even after viral suppression with antiretroviral therapy (ART). Although chronic opioid exposure is associated with adverse clinical outcomes, its impact on immune homeostasis during ART remains incompletely understood. We investigated whether opioid use disorder (OUD) is associated with persistent systemic and cellular immune dysregulation despite ART-mediated reductions in HIV viral load (VL). Methods: Peripheral blood was collected longitudinally from PWH with OUD (PWH/OUD+) and detectable HIV VL during 6 months of optimized ART (months 0, 3, and 6). A reference cohort of PWH without OUD (PWH/OUD-) and suppressed HIV VL provided a single blood sample. Immune profiling included plasma inflammatory biomarkers, multiplex cytokine analyses, spectral flow cytometry, and assessment of monocyte cytokine responses following lipopolysaccharide (LPS) stimulation. Mixed-effects models adjusted for HIV VL and VL-stratified analyses were performed. Results: PWH/OUD+ exhibited persistent immune dysregulation despite reductions in HIV VL. Plasma sCD163, sCD14, fractalkine, and I-TAC remained elevated, whereas TGF-{beta}1 was reduced. OUD was associated with expansion of CD16 monocytes and altered expression of CCR2, CD38, and CD11b. CD4 and CD8 T cells, NK cells, and B cells also exhibited persistent alterations in markers of activation, metabolism, and trafficking. Monocytes from PWH/OUD+ displayed attenuated cytokine responses following LPS stimulation. Conclusions: OUD is associated with persistent systemic and cellular immune dysfunction in PWH despite ART-mediated viral suppression, supporting opioid exposure as an independent contributor to chronic immune dysregulation that may promote inflammation, immune dysfunction, and long-term HIV-associated comorbidities. Keywords: HIV, Opioid-use disorder, innate immunity, cytokine

immunology↗

The mitochondrial RNA extrusion-induced innate immunity is regulated by N6-methyladenosine machinery

Mitochondrial RNA (mtRNA) released into the cytosol functions as a damage associated molecular pattern that activates pattern-recognition receptor (PRR)-mediated inflammation, yet its release mechanisms and cytoplasmic fate remain poorly understood. Here we report that chemical Abt-373-treatment and Vesicular stomatitis virus (VSV) infection induce mtRNA extrusion through Bax/Bak and VDAC1 channels, accompanied by mtDNA release. Extruded mtRNA in A549 cells activates multiple cytosolic PRRs, including RIG-I, MDA5, TLR3/7/8, and PKR, each contributing differentially to the innate immune signaling. Analysis of GEO datasets and methylated RNA immunoprecipitation (MeRIP) assays further reveals that mtRNA carries methyladenosine (m6A) modification. m6A machinery proteins are involved in the cytoplasmic retention time of mtRNA and its interaction with RIG-I, thereby modulating mtRNA-induced innate immunity. Thus, our work establishes in vitro models of mtRNA extrusion, and highlights m6A-dependent modulation as a potential therapeutic target for mtRNA-driven inflammation.

immunology↗